Manuscript ID

MS-2023-0042

Journal

Nature Biotechnology

Current Status

Under Review

First Submitted

Jun 18, 2023

Latest Version

v2.0 (Jul 12, 2023)

Corresponding Author

Dr. Michael Chen

Version Timeline

v2.0
Current Version Under Review
Jul 12, 2023

Revised manuscript addressing reviewer comments on methodology and results interpretation.

Main Text (revised) Figures (revised) Supplementary Materials Response to Reviewers
Reviewer Comments Received Jul 2, 2023

3 reviewers provided feedback on the initial submission.

Reviewer #1: The methodology needs further clarification, particularly regarding the CRISPR design strategy.

Minor Revision

Reviewer #2: Results are promising but additional control experiments are needed to support conclusions.

Major Revision

Reviewer #3: Well-designed study with novel insights. Minor edits to discussion recommended.

Accept with Minor Changes
v1.0
Initial Submission
Jun 18, 2023

Original manuscript submission with complete methodology, results, and discussion.

Main Text Figures (6) Supplementary Materials Cover Letter
Draft
Draft Created Jun 5, 2023

Initial draft manuscript created in the system with preliminary data and abstract.

Version Comparison

Version 1.0 (Initial)
Version 2.0 (Current)

CRISPR-Cas9 gene editing has emerged as a powerful tool for targeted genetic modifications. In this study, we developed a novel approach for enhancing the efficiency of CRISPR-mediated gene editing in cancer cells.

Our method utilizes a modified guide RNA structure that improves target specificity while reducing off-target effects.

Experimental results demonstrate a significant improvement in editing efficiency across multiple cancer cell lines, including those resistant to conventional therapies.

CRISPR-Cas9 gene editing has emerged as a powerful tool for targeted genetic modifications. In this study, we developed a novel dual-guide RNA system for enhancing both the specificity and efficiency of CRISPR-mediated gene editing in various cancer cell types.

Our method utilizes a chemically modified guide RNA structure with improved stability that improves target specificity while reducing off-target effects.

Experimental results demonstrate a 2.5-fold improvement in editing efficiency (p<0.001) across multiple cancer cell lines, including those resistant to conventional therapies.

Page 1 of 15

Upload New Version

Drag and drop your file here, or browse

Max file size: 25MB

Drag and drop your file here, or browse

Max file size: 50MB

Drag and drop your file here, or browse

Max file size: 100MB

Drag and drop your file here, or browse

Max file size: 25MB